CKD Bio종근당바이오
063160 · KOSPI · ₩063160 · 종근당바이오
- Market cap
- ₩68B
- Enterprise value
- ₩214B
- P/E
- —
- P/B
- 0.6×
- Dividend yield
- 0.0%
- ROE
- −6.5%
- Net margin
- −4.9%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−50.3% from the high
₩11,770Today: ₩12,060 – ₩12,380₩24,900
Returns
- 1W−5.0%
- 1M−5.6%
- 3M+1.5%
- 6M−36.9%
- YTD−39.2%
- 1Y−43.2%
- Volume today
- 7,412
- 0.2× the 20-day average
- Traded today
- ₩91M
- Listed shares
- 5,485,962
- EPS (12 months)
- −₩1,424
- Earnings yield −11.5%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 27 of 100 (50 is a normal day for this stock).
- MomentumFlat-3.4% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
CKD Bio stock overview
CKD Bio (종근당바이오, KRX: 063160) is listed on KOSPI, in the Biotech & Pharma sector. Jongkundang Bio is a Korean fermentation and biotech company, spun off in 2001 from Chong Kun Dang, that produces active pharmaceutical ingredients (APIs) such as antibiotics, cardiovascular and immunosuppressant ingredients, and probiotics for health functional foods. Its shares closed at ₩12,380 on Oct 28, 2026, up 2.31% on the day, giving it a market value of ₩68B.
Key facts
- Market cap
- ₩68B
- Sector
- Biotech & Pharma
- Latest price change
- +2.31%
- As of
- Oct 28, 2026
- Main business
- Jongkundang Bio is a Korean fermentation and biotech company, spun off in 2001 from Chong Kun Dang, that produces active pharmaceutical ingredients (APIs) such as antibiotics, cardiovascular and immunosuppressant ingredients, and probiotics for health functional foods.
Quick answers about CKD Bio
- What does CKD Bio do?
- Jongkundang Bio is a Korean fermentation and biotech company, spun off in 2001 from Chong Kun Dang, that produces active pharmaceutical ingredients (APIs) such as antibiotics, cardiovascular and immunosuppressant ingredients, and probiotics for health functional foods. It also operates a microbiome CDMO business, and has launched a botulinum toxin product in South Korea. The company runs production sites in Ansan, Ocheon and Yesan and supplies its products to customers in about 40 countries.
- What is the market cap of CKD Bio?
- The market capitalisation of CKD Bio was ₩68B at the close on Oct 28, 2026.
- Who are the largest shareholders of CKD Bio?
- According to the latest official filings, the largest reported holders are National Pension Service (0.62%, as of Dec 31, 2025).
- When is the next earnings report from CKD Bio?
- Korean companies rarely announce results dates in advance. Based on when CKD Bio filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own CKD Bio?
- Yes. The National Pension Service held 0.62% of CKD Bio shares as of Dec 31, 2025.
Company profile
Jongkundang Bio is a Korean fermentation and biotech company, spun off in 2001 from Chong Kun Dang, that produces active pharmaceutical ingredients (APIs) such as antibiotics, cardiovascular and immunosuppressant ingredients, and probiotics for health functional foods. It also operates a microbiome CDMO business, and has launched a botulinum toxin product in South Korea. The company runs production sites in Ansan, Ocheon and Yesan and supplies its products to customers in about 40 countries.
Written by AI from the company's latest annual report.
- Korean name
- 종근당바이오
- Sector
- Biotech & Pharma
- Themes
- Biosimilars
- CEO
- 박완갑
- Founded
- Nov 2001
- Listed
- Dec 2001
- Listed shares
- 5,485,962
- Fiscal year ends
- Month 12
- Website
- www.ckdbio.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent filings
See all- Major management matter relevant to investorsAug 14, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Preliminary earningsJul 31, 2026
- Disclosure Related to Sustainability Management Report, etc. (Voluntary Disclosure)Jun 26, 2026
- Disclosure of Corporate Governance ReportJun 1, 2026
Titles in Korean until English translations are added.
Also known as: CKD Bio / 종근당바이오 / 063160 / KRX:063160
Source: KRX statistical information